Post-approval studies (Phase 4)Study completedNCT02596009
What this trial is testing
Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices
Who this might be right for
Pulmonary Disease, Chronic Obstructive (COPD)
Novartis Pharmaceuticals 97